<?xml version='1.0' encoding='utf-8'?>
<document id="23313623"><sentence text="OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485."><entity charOffset="56-65" id="DDI-PubMed.23313623.s1.e0" text="entecavir" /></sentence><sentence text="Entecavir and JBP485 (a dipeptide) exhibit the antihepatitis activities and it is possible for the two drugs to be coadministered in the treatment of hepatitis"><entity charOffset="0-9" id="DDI-PubMed.23313623.s2.e0" text="Entecavir" /></sentence><sentence text=" We aimed to elucidate whether entecavir was a substrate of OAT1, OAT3, OCT, and PEPT1 and to investigate the targets of drug-drug interactions between entecavir and JBP485"><entity charOffset="31-40" id="DDI-PubMed.23313623.s3.e0" text="entecavir" /><entity charOffset="152-161" id="DDI-PubMed.23313623.s3.e1" text="entecavir" /><pair ddi="false" e1="DDI-PubMed.23313623.s3.e0" e2="DDI-PubMed.23313623.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23313623.s3.e0" e2="DDI-PubMed.23313623.s3.e1" /></sentence><sentence text=" Plasma and urine concentrations of entecavir following intravenous and oral administration in vivo, uptake of entecavir in kidney slices and transfected cells in vitro, were determined by LC-MS/MS"><entity charOffset="36-45" id="DDI-PubMed.23313623.s4.e0" text="entecavir" /><entity charOffset="111-120" id="DDI-PubMed.23313623.s4.e1" text="entecavir" /><pair ddi="false" e1="DDI-PubMed.23313623.s4.e0" e2="DDI-PubMed.23313623.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23313623.s4.e0" e2="DDI-PubMed.23313623.s4.e1" /></sentence><sentence text=" Following intravenous co-administration of entecavir and JBP485 in rats, entecavir AUC increased 1"><entity charOffset="44-53" id="DDI-PubMed.23313623.s5.e0" text="entecavir" /><entity charOffset="74-83" id="DDI-PubMed.23313623.s5.e1" text="entecavir" /><pair ddi="false" e1="DDI-PubMed.23313623.s5.e0" e2="DDI-PubMed.23313623.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23313623.s5.e0" e2="DDI-PubMed.23313623.s5.e1" /></sentence><sentence text="93-fold, t1/2β was prolonged 2" /><sentence text="08-fold, CLP decreased 49%, CLR decreased 73%, and accumulated urinary excretion decreased 54%" /><sentence text=" However, following oral co-administration, the entecavir Tmax and Cmax were not affected; the degree of change in other pharmacokinetic parameters (AUC, t1/2β, CLP, and accumulated urinary excretion) was similar to that of intravenous administration"><entity charOffset="48-57" id="DDI-PubMed.23313623.s8.e0" text="entecavir" /></sentence><sentence text=" The uptake of entecavir was nearly identical in hPEPT1- as in vector-HELA cells"><entity charOffset="15-24" id="DDI-PubMed.23313623.s9.e0" text="entecavir" /></sentence><sentence text=" In rat kidney slices, uptake of entecavir was markedly inhibited by p-aminohippurate, benzylpenicillin, JBP485, and tetraethyl ammonium"><entity charOffset="33-42" id="DDI-PubMed.23313623.s10.e0" text="entecavir" /><entity charOffset="69-85" id="DDI-PubMed.23313623.s10.e1" text="p-aminohippurate" /><entity charOffset="87-103" id="DDI-PubMed.23313623.s10.e2" text="benzylpenicillin" /><entity charOffset="105-111" id="DDI-PubMed.23313623.s10.e3" text="JBP485" /><entity charOffset="117-136" id="DDI-PubMed.23313623.s10.e4" text="tetraethyl ammonium" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e0" e2="DDI-PubMed.23313623.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e0" e2="DDI-PubMed.23313623.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e0" e2="DDI-PubMed.23313623.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e0" e2="DDI-PubMed.23313623.s10.e3" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e0" e2="DDI-PubMed.23313623.s10.e4" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e1" e2="DDI-PubMed.23313623.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e1" e2="DDI-PubMed.23313623.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e1" e2="DDI-PubMed.23313623.s10.e3" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e1" e2="DDI-PubMed.23313623.s10.e4" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e2" e2="DDI-PubMed.23313623.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e2" e2="DDI-PubMed.23313623.s10.e3" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e2" e2="DDI-PubMed.23313623.s10.e4" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e3" e2="DDI-PubMed.23313623.s10.e3" /><pair ddi="false" e1="DDI-PubMed.23313623.s10.e3" e2="DDI-PubMed.23313623.s10.e4" /></sentence><sentence text=" In hOAT1- and hOAT3-HEK293 cells, uptake of entecavir was significantly higher compared to vector-HEK293 cells and was markedly inhibited by p-aminohippurate, benzylpenicillin, and JBP485"><entity charOffset="45-54" id="DDI-PubMed.23313623.s11.e0" text="entecavir" /><entity charOffset="142-158" id="DDI-PubMed.23313623.s11.e1" text="p-aminohippurate" /><entity charOffset="160-176" id="DDI-PubMed.23313623.s11.e2" text="benzylpenicillin" /><pair ddi="false" e1="DDI-PubMed.23313623.s11.e0" e2="DDI-PubMed.23313623.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23313623.s11.e0" e2="DDI-PubMed.23313623.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23313623.s11.e0" e2="DDI-PubMed.23313623.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23313623.s11.e1" e2="DDI-PubMed.23313623.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23313623.s11.e1" e2="DDI-PubMed.23313623.s11.e2" /></sentence><sentence text=" Km and Vmax values of entecavir were 250 μM and 0"><entity charOffset="23-32" id="DDI-PubMed.23313623.s12.e0" text="entecavir" /></sentence><sentence text="83 nmol/mg protein/30s (OAT1) and 23 μM and 1" /><sentence text="1 nmol/mg protein/30 s (OAT3), respectively" /><sentence text=" Entecavir is the substrate of OAT1, OAT3, and OCT"><entity charOffset="1-10" id="DDI-PubMed.23313623.s15.e0" text="Entecavir" /></sentence><sentence text=" Moreover, OAT1 and OAT3 are the targets of DDI between entecavir and JBP485"><entity charOffset="56-65" id="DDI-PubMed.23313623.s16.e0" text="entecavir" /></sentence><sentence text="" /></document>